Assembly Pharmaceuticals, Inc. Transaction (Tables)

3 Months Ended

Mar. 31, 2015

The allocation of the purchase price to the Assembly balance sheet is shown below:

Cash and cash equivalents	$	509,363
Other current assets		23,540
Equipment, net		10,350
In-process research and development		29,000,000
Goodwill		12,737,350
Security deposits		16,606
Total assets		42,297,209

Accrued expenses		874,113
Deferred tax liability		11,600,000
Total liabilities		12,474,113
Net assets acquired	$	29,823,096

Pro Forma

	Three Months Ended March 31,
	2014
Revenues	$	-
Net loss		(4,495,684)
Loss per share - basic and diluted	$	(0.54)